New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 12, 2014
08:09 EDTVRX, ACTActavis announces patent challenge settlement for Acanya
Actavis (ACT) announced that it has entered into an agreement with Valeant (VRX) to settle all outstanding patent litigation related to Actavis' generic version of Acanya Gel, 1.2%/2.5%. Acanya Gel is a lincosamide antibiotic and benzoyl peroxide indicated for the topical treatment of acne vulgaris. Under the terms of the agreement, Valeant will grant Actavis a license to market its generic Acanya Gel beginning in July 1, 2018 or earlier under certain circumstances. Other details of the settlement were not disclosed. For the 12 months ending February 28, Acanyaź had total U.S. sales of approximately $121M, according to IMS Health data.
News For ACT;VRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
January 14, 2015
16:59 EDTACTGalena, Orexo AB receive "Paragraph IV" patent certification notice from Actavis
Subscribe for More Information
January 13, 2015
14:00 EDTACTActavis says Allergan deal could close as early as Q1, as late as Q2
Subscribe for More Information
13:49 EDTACTActavis says sees about $8B in free cash flow in 2016
Subscribe for More Information
13:42 EDTACTActavis targeting 2017 EPS of $25
Subscribe for More Information
13:38 EDTACTActavis sees Q4 adjusted EPS beating consensus by 10%-15%
Subscribe for More Information
12:49 EDTVRXValeant CEO says 'unlikely' to work with Bill Ackman again
Subscribe for More Information
12:48 EDTVRXValeant CEO says will have a 'number of clean quarters in a row'
Valeant CEO Michael Pearson said on CNBC that his company will have a "number of clean quarters in a row" in an effort to dispute attacks on its business model.
10:56 EDTVRXValeant sees continuation of Q3 trends in Q4
Subscribe for More Information
10:46 EDTVRXValeant doesn't see need to 'push a large deal for sake of doing large deal'
Sees double digit organic growth in 2014, 2015 and beyond. Says business development a priority for cash flow. Sees pursuing small and medium sized deals. Says doesn't see a need to "push a large deal for the sake of doing a large deal." Comments made at the JP Morgan Healthcare Conference. Valeant shares are up 2.1% to $158.76 in morning trading.
10:39 EDTVRXValeant repeats FY15 EPS view $10.10-$10.40, revenue $9.2B-$9.3B
Subscribe for More Information
10:38 EDTVRXValeant repeats Q4 cash EPS view $2.55+ vs. previous view $2.45-$2.55
Repeats Q4 revenue view $2.1B-$2.3B. Sees Q4 adjusted cash flow from operations about $600M. Says absorbed additional negative Fx impact of ~$40M to revenue, ~10c to cash EPS. Says FDA submission for Vesneo on track for Q2. Sees submission for sub-micron loteprednol gel 0.38% in late Q3, early Q4, and expects to launch product in 3Q16. Sees filing NDA for Arestin LCM in 2H15. Sees >12% same store organic growth for total company in Q4, >10% for FY. Sees Bausch + Lomb organic growth >10% for FY. Sees continued strong performance from Jublia, other recent product launches. Strategic initiates for 2015 include 10%-12% organic growth, cash conversion rate of >90%, achieve $500M+ revenues for key launch programs, including Jublia, Ultra, Luzu, Retin-A Micro 0.08%, Onexton. Comments from slides being presented at the JP Morgan Healthcare Conference.
08:05 EDTACTActavis launches US generic specialty injectable portfolio
Actavis announced the launch of a portfolio of generic specialty injectable medications to be marketed to hospitals across the United States. Actavis will immediately begin marketing approximately 20 injectable products across a number of therapeutic categories in the U.S. The company hopes to be a leader in Oncology, with nearly a dozen marketed products including generic versions of Gemzar, Taxotere, Campostar and Zometa. Actavis also has an industry leading specialty injectable pipeline, with approximately 20 new filings under review at the U.S. Food and Drug Administration, as well as more than 50 additional projects currently in development.
07:42 EDTVRXJPMorgan to hold a conference
33rd Annual Healthcare Conference is being held in San Francisco on January 12-15 with webcasted company presentations to begin on January 13 at 10:30 am; not all company presentations may be webcasted. Webcast Link
07:39 EDTVRXAmerican Academy of Cosmetic Surgery to hold a meeting
Subscribe for More Information
January 12, 2015
12:45 EDTACTActavis CEO says 'can't speculate on what Pfizer is going to do'
Subscribe for More Information
12:10 EDTACTRBC Capital says Celgene's shares could rise to $200 'over time'
The long-term profit guidance that Celgene (CELG) released today suggests that the stock, currently trading around $115, could reach $200 "over time," RBC Capital wrote in a note to investors today. WHAT'S NEW: After Celgene estimated that its EPS would exceed $12.50, excluding certain items, by 2020, RBC Capital says that the guidance exceeded the firm's previous outlook. RBC added that Celgene's projection increases its confidence in the predictability of the drug maker's performance over the longer term. The firm recommended that investors own Celgene in 2015, noting that the company has the potential to settle its patent case with Actavis (ACT). A settlement would enable investors to focus on Celgene's visible long-term growth and the robust opportunity provided by its drugs in development, RBC stated. Historically, investors have not given Celgene credit for these strengths, the firm stated. PRICE ACTION: In early afternoon trading, Celgene rose 1.5% to $115.35.
09:37 EDTACTSupreme Court rejects Allergan appeal on generic Latisse, Bloomberg reports
08:34 EDTACTActavis expects Q4 non-GAAP EPS to exceed consensus by 10%-15%
Subscribe for More Information
08:09 EDTACTActavis and Allergan announce early termination of HSR waiting period
Subscribe for More Information
08:07 EDTACTActavis, Allergan announce early termination of Hart Scott Rodino waiting period
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use